Prof Patricia Campbell

Can what’s on your plate help treat heart failure? 🍽️

@robmentz.bsky.social dives into what a decade of research says about medically tailored meals, and why they might be part of the future of HF care. 🫀

For more details on the study: bit.ly/4lk70EW

AI tools used by English councils downplay women’s health issues, study finds Exclusive: LSE research finds risk of gender bias in care decisions made based on AI summaries of case notes Artificial intelligence tools used by more than half of England’s councils are downplaying women’s physical and mental health issues and risk creating gender bias in care decisions, research has found. The study found that when using Google’s AI tool “Gemma” to generate and summarise the same case notes, language such as “disabled”, “unable” and “complex” appeared significantly more often in descriptions of men than women. Continue reading...

AI tools used by English councils downplay women’s health issues, study finds

Always the best bit of the conference - debate with the hilarious but profoundly clever Will Watson insisting interventionalists stay away from HF! #BSHMDT2025

Don’t forget immunofixation if testing for AL amyloidosis! Could miss 2% of AL…
Brilliant practical talk from Geraint Jenkins here at @BSHeartFailure @BSHnurseforum @NIHFNF #25in25 #mdt2025

HFpEF session kicked off here at the first BSH MDT meeting in beautiful Cardiff, with a practical work up lecture by the amazing Becky Hyland #25in25

Phenomenal multimodality imaging session here at Advanced Imaging 2025 @bsecho.bsky.social @roysocmed.bsky.social @rositazakeri.bsky.social taught me so more MRI tips today than I have ever known 🥰

RESHAPE showed reduction of rate of HFH but little impact on CV death, number events - due to low proportionality of MR!

Proportionality of MR matters for outcome of Functional MR intervention trials! Brilliant insights from Liam Ring @bsecho.bsky.social @roysocmed.bsky.social

Off to a flying start here at Advanced Imaging 2025 here @roysocmed.bsky.social with @bsecho.bsky.social
Loving this theory of maldistribution of workload predicting response to CRT

Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial Semaglutide increased walking distance in patients with symptomatic peripheral artery disease and type 2 diabetes. Research implications include the need for future studies to further elucidate mechan...

"Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial."
Présenté ce jour à #ACC25 et publié dans @thelancet.bsky.social.
#MedSky #CardioSky
www.thelancet.com/journals/lan...

Are we at an AI tipping point? What are the the challenges? Interesting session on AI #acc25 #AI @accintouch.bsky.social

Figure 2. Cumulative Incidence of New-Onset Atrial Fibrillation or Atrial Flutter in Patients Randomized to Receive Finerenone or Placebo

From JAMA Cardiology: Finerenone was effective in heart failure patients with mildly reduced or preserved ejection fraction, regardless of atrial fibrillation (AF) status, and new-onset AF was linked to higher risk of adverse outcomes.

#ACC25 https://ja.ma/4iKwgDk

Check out @drmarthagulati.bsky.social’s insights on the WARRIOR Trial

#ESCTVOnTheRoad #ACC245

🫶 @womensheart.bsky.social #ACC25

Exciting! #STRIDE trial just presented at #ACC25 @accintouch.bsky.social . #Semaglutide improved mean walking distance, symptoms, major limb events & quality of life in patients with #T2D & #PAD. We have a new drug now to help PAD patients! #CardioSky

The STRIDE trial demonstrated that semaglutide significantly improves function, symptoms, and health-related QoL in patients with symptomatic #cvPAD and T2DM.

Get the full clinical trial details here ➡️ bit.ly/42dnA1n #ACC25 #CardioSky #MedSky

Intensive medical therapy did not significantly impact the rate of serious CV events at five years in women w/ suspected INOCA, according to findings from WARRIOR presented during a #LBCT session at #ACC25.

Learn more: bit.ly/44a7uYO #MedSky #CardioSky

Done! ✅

Do you practice in #HeartFailure?
Then please do this survey for @noshreza.bsky.social Dr MarkDrazner Dr. Olivia Gilbert et al!
They want to hear about practicing heart failure specialists #HFAwareness #heartmonth #CardioSky

redcap.wakehealth.edu/redcap/surve...

🙏♥️❤️‍🩹🫀

Happiest birthday Binkley, what a gorgeous dog born on a gorgeous day ❤️

Baroreflex activation therapy modulates baroreceptor nerve activity, & has been shown to improve exercise capacity & QoL in HFrEF.

This JCF brief report presents a real-world analysis showing that BAT reduces hospital visits & LoS.

#THT2025

🔗 bit.ly/4aW92Y2

Food for thought? Maybe because access to these interventions will always be limited where I am, but I am always sceptical. Ready to be proven wrong

🚨New science alert! HM3 LVADs are associated w/hemodynamic related events like RVF.

In this prospective RCT, pts who received a novel RV protection strategy upfront post-LVAD implant had better outcomes & less RVF.

#THT2025

🔗: bit.ly/3CEDDN7

🫀 A new study validates the SPICT (Supportive and Palliative Care Indicator Tool), which identifies hospitalized HF pts at high mortality risk.

Key Findings:
✔ SPICT-JP +: >3x ⬆️ mort risk
✔ Aids in advance-care planning for EoL decisions.

🔗https://bit.ly/4g0Lou8

Love this paper - it’s a question I ponder daily

Current guidelines for primary prev ICD might not apply to contemporary pts given advances in HF Rx. Or do they?

🌟 This joint publication in #JCF & @hrs_journal summarizes data to date and proposes clinical trial to reassess.

🔗 bit.ly/3CEUj7a

This 🔥 new brief report describes a first-in-human feasibility study to evaluate the safety/efficacy of the Reprieve System, a bedside fluid mgmnt device that can
1) measure UO
2) semi-auto titrate IV diuretics
3) titrate saline replacement

#THT2025

🔗 bit.ly/4huGrvq

Acute HF differs from chronic HF, especially in HFmrEF/HFpEF, due to marked neurohormonal activation, which serves as a therapeutic target.

In this 🔥 Perspectives piece, the authors describe the role of rapid uptitration of neurohormonal blockade in these pts👇

🔗 bit.ly/4gF4ned

Is TTR biology the sole driver of disease progression? In an era of multiple therapies for ATTR-CM, is choosing one disease-modifying agent over another as important as early disease recognition & treatment?

Dr. Mathew Maurer tackles this question!

bit.ly/42MGNZN

New science 🚨!

In this new 🔥#JCFIgnite! Dr. Yogita Rochlani, Dr. Enklajd Marsela, and Dr. Ulrich Jorde discuss the evidence behind the AccuCinch device, the CorCinch-HF trial & the potential & limitations of this novel therapy.

#THT2025

🔗 bit.ly/3CC3WUb